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Before fertilization, vertebrate eggs are arrested in meiosis II by
cytostatic factor (CSF), which holds the anaphase-promoting com-
plex (APC) in an inactive state. It was recently reported that Mos,
an integral component of CSF, acts in part by promoting the
Rsk-mediated phosphorylation of the APC inhibitor Emi2/Erp1. We
report here that Rsk phosphorylation of Emi2 promotes its inter-
action with the protein phosphatase PP2A. Emi2 residues adjacent
to the Rsk phosphorylation site were important for PP2A binding.
An Emi2 mutant that retained Rsk phosphorylation but lacked
PP2A binding could not be modulated by Mos. PP2A bound to Emi2
acted on two distinct clusters of sites phosphorylated by Cdc2, one
responsible for modulating its stability during CSF arrest and one
that controls binding to the APC. These findings provide a molec-
ular mechanism for Mos action in promoting CSF arrest and also
define an unusual mechanism, whereby protein phosphorylation
recruits a phosphatase for dephosphorylation of distinct sites
phosphorylated by another kinase.
anaphase-promoting complex  cytostatic factor Cdc2  cyclin B  meiosis 
phosphatase
Vertebrate eggs are arrested in metaphase II of meiosis by anactivity known as cytostatic factor (CSF) (1). During CSF
arrest, the anaphase-promoting complex (APC) is inhibited,
preventing degradation of cyclin B and other substrates neces-
sary for maintenance of M phase.
A key component of CSF activity is contributed by Mos, an
upstream activator of the MEK/MAPK/p90Rsk pathway (2–5).
Inhibition of this pathway causes failure to stably arrest in
meiosis II, whereas ectopic Mos expression in the early cleavage
embryo (or in Xenopus egg extracts prepared to mimic these
early cleavages) induces a CSF-like M phase arrest, inhibiting
APC activation.
Recently, the APC inhibitor Emi2 has been implicated as a
component of CSF (6–11). Emi2 is a zinc finger-containing
protein whose binding to the APC inhibits APC function (12).
During CSF arrest, Emi2 is bound to the APC, preventing
substrate degradation. Upon fertilization, CaMKII-mediated
phosphorylation of Emi2 promotes docking of Polo-like kinase
1 (Plx1 in Xenopus) and subsequent Plx1-mediated Emi2 phos-
phorylation (13–15). This phosphorylation creates a phospho-
degron for the E3 ubiquitin ligase SCFTrCP, leading to rapid
Emi2 degradation, alleviating APC inhibition, and promoting M
phase exit into the first embryonic interphase.
Emi2 regulation can be reconstituted in extracts prepared
from Xenopus eggs. Inclusion of a calcium chelator in the lysis
buffer yields a CSF-arrested extract that can be released into
interphase by calcium addition. Analysis of Emi2 in this system
has revealed an additional level of regulation distinct from the
rapid destruction promoted by CaMKII/Plx1. Because cyclin B
synthesis continues during CSF arrest, Cdc2/cyclin B kinase
activity could rise unabated if synthesis were not counterbal-
anced by ongoing slow cyclin B degradation. As we reported
recently, this degradation is positively regulated through Cdc2-
mediated Emi2 phosphorylation (12, 16). Phosphorylation of
Emi2 near its C terminus weakens the Emi2–APC interaction,
allowing slow cyclin B degradation. Once cyclin levels and Cdc2
kinase activity recede to a certain threshold, dephosphorylation
of Emi2 at the Cdc2 phosphorylation sites restores Emi2 activity,
halting further cyclin degradation. These findings suggested the
existence of a regulatory loop consisting of Cdc2 and an Emi2-
directed phosphatase. Inhibitor and protein interaction studies
showed this dephosphorylation to be catalyzed by PP2A.
Despite their importance for CSF activity, it was unclear
whether Emi2 and Mos acted independently or worked coop-
eratively to promote and maintain CSF arrest. Recently, how-
ever, it was demonstrated that Mos-activated Rsk phosphory-
lates Emi2, which somehow promotes Emi2 stability and
function (17, 18). We show here that Rsk phosphorylation of
Emi2 promotes recruitment of PP2A to Emi2. Further, Rsk
phosphorylation does not enhance Emi2 function or stability
when Emi2 is mutated to abrogate PP2A binding. PP2A binding
to Emi2modulates not only dephosphorylation of the C-terminal
Cdc2 sites to control APC binding, but also a set of previously
uncharacterized N-terminal Cdc2 sites that control the slow
turnover of Emi2 during M phase arrest. These results suggest
that the homeostatic levels, and not simply APC-binding capac-
ity, of Emi2 are actively maintained during CSF arrest. Collec-
tively, these findings provide a mechanistic explanation for the
ability of Mos to promote CSF arrest through PP2A-mediated
control of both function and stability of Emi2.
Results
Mos-Induced CSF Arrest Requires Emi2.AlthoughMos levels are low
or undetectable during interphase in cycling egg extracts, addi-
tion of exogenous Mos can promote an M phase arrest as the
extract enters mitosis. This CSF-like arrest is typified by the
stabilization of cyclin B, but not cyclin A (Fig. 1A), and Ca2
addition promotes cyclin B degradation and reentry into the
interphase [supporting information (SI) Fig. 5]. Because Mos-
induced arrest is manifested as inhibition of the APC, we wished
to determine whether this arrest required the APC inhibitor
Emi2. Because Emi2 is destroyed before exit from CSF arrest,
Emi2 levels are low as the first embryonic interphase begins.
Thus, we can treat cycling extracts in this first interphase with
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morpholino antisense oligonucleotides complementary to the 5
untranslated region of Emi2 mRNA to inhibit Emi2 reaccumu-
lation (11). The Emi2 morpholinos dampened Emi2 translation
without affecting cyclin B accumulation (Fig. 1B and SI Fig. 6).
Mos no longer induced M phase arrest when Emi2 levels were
decreased, as evidenced by an inability to prevent cyclin B
degradation (Fig. 1B). (Note that Emi2 levels were analyzed in
separate reactions because our anti-Emi2 antibodies, raised
against an MBP fusion protein, strongly cross-react with the
MBP-Mos, which migrated at the same gel position as Emi2.)
Moreover, readdition of 15-nM Emi2 (a level comparable to that
found in CSF extracts) (17) restored the ability of ectopic Mos
to induce M phase arrest in Emi2-depleted cycling extracts,
whereas readdition of Emi2 alone had no effect (Fig. 1C),
confirming recently published reports that Mos exerts its effects
through Emi2 (17, 18).
Mos Enhances Emi2-Mediated APC Inhibition by Promoting T545/551
Dephosphorylation. The ability of Emi2 to maintain APC inhibi-
tion during CSF arrest can be controlled through Cdc2-mediated
phosphorylation at two residues in the C-terminal region of the
protein, T545 and T551 (12, 16). Phosphorylation of these sites
promotes Emi2 dissociation from the APC, thereby enhancing
degradation of APC substrates without affecting Emi2 stability.
Because Mos-induced CSF arrest required Emi2, we postulated
that Mos might regulate Emi2 phosphorylation to control Emi2–
APC interaction. Emi2 in cycling extracts displayed a pro-
nounced shift in its electrophoretic mobility coincident with
Cdc2 activation (SI Fig. 7A) (8), which shift was collapsed by
-phosphatase treatment (SI Fig. 7B). However, we observed
that, duringMos-inducedM phase arrest, the Emi2 mobility shift
was markedly dampened, suggesting that Mos opposes the
extensive phosphorylation of Emi2 during M phase (SI Fig. 7A).
Supporting this idea, we found that the MEK inhibitor U0126
increased Emi2 phosphorylation in CSF extracts, as indicated by
an upshift in Emi2 gel mobility (Fig. 2A and SI Fig. 7C). This
mobility shift made it difficult to ascertain whether Emi2’s
stability had been affected by inhibition of Mos/MAPK signal-
ing. Thus, we treated samples with -phosphatase before SDS/
PAGE and found that MAPK inhibition partially destabilized
Emi2 and also promoted CSF exit (Fig. 2B).
To address Mos/MAPK effects on phospho T545/551-
regulated Emi2 activity independent of effects on Emi2 stability,
we used a nondegradable fragment of Emi2. Inhibition of the
Mos-activated kinase Rsk by SL0101 (18) promoted partial
Fig. 1. Mos requires Emi2 to induce M phase arrest. (A) Cycling extracts were
incubated at room temperature for 45 min and were then supplemented with
MBP or MBP-Mos. Aliquots were withdrawn at indicated times and immuno-
blotted for phosphoMAPK (pMAPK), cyclin B2, cyclin A, and phosphoCdc2
(pCdc2). (B) Two sets of cycling extracts in the presence of control or Emi2
antisense morpholinos were incubated at room temperature for 45 min. Mos
protein was added to one set of the extracts. Samples were taken at indicated
times. Samples taken from extracts without Mos were used to immunoblot for
Emi2, and samples taken from extracts with Mos were used to immunoblot for
pMAPK and cyclin B2. The asterisk marks a nonspecific band. (C) Cycling
extracts were incubated at room temperature in the presence of Emi2 anti-
sense morpholinos. After 45 min, Mos protein, Emi2 protein, or both were
added. Samples were taken at indicated times, and pMAPK and cyclin B2 were
examined by immunoblotting.
Fig. 2. Mos regulates Emi2 T545/551 dephosphorylation. (A) CSF extracts
were incubated at room temperature in the presence of DMSO or 200 M
U0126. Samples were taken at the indicated times and were immunoblotted
for pMAPK and Emi2. Arrows indicate Emi2 mobility shift. (B) CSF extracts were
incubated at room temperature in the presence of DMSO or 250M U0126. At
the indicated times, samples were withdrawn to examine pMAPK and cyclin
B2. Samples were also taken to examine endogenous Emi2 after -phospha-
tase treatment and to measure Cdc2/cyclin B kinase activity. (C) (Upper) CSF
extracts were supplemented with 40 nM nondegradable cyclin B1. After 90
min, IVT 35S-labeled Emi2 was added in the presence or absence of Rsk
inhibitor, SL0101. After 30 min of incubation, Cdc27 was immunoprecipitated
and washed, and bound Emi2 was examined by SDS/PAGE and autoradiogra-
phy. (Lower) The amount of 35S-labeled Emi2 bound to Cdc27 was quantified,
normalized, and plotted. Error bars represent the standard deviation of three
replicates. (D) Cycling extracts were incubated at room temperature in the
presence of MBP, MBP-Emi2 (489–651) WT, or MBP-Emi2 (489–651) T545/
551A proteins. Samples were taken at indicated times, and levels of cyclins A
and B2 were examined by immunoblotting. (E) (Left) GST-Emi2 (326–651)
bound to glutathione Sepharose was phosphorylated in vitrowith Cdc2/cyclin
B and [-32P]ATP and then incubated in interphase extracts pretreated with
MBP or MBP-Mos. At indicated times, beads were washed, and the remaining
phospho-Emi2 was examined by SDS/PAGE and autoradiography. (Right) The
amount of 32P-labeled Emi2 remaining was quantified, normalized, and plot-
ted. Each column represents the average of three replicates, and error bars
represent the standard deviation.
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dissociation of Emi2 from the APC in CSF extracts (Fig. 2C).
APC binding of Emi2 lacking the Cdc2 phosphorylation sites
(T545/551A) was noticeably less affected by Rsk inhibition,
supporting the notion that Mos/MAPK signaling promotes
cyclin stability at least in part through opposing Cdc2-induced
Emi2–APC dissociation (Fig. 2C). Moreover, 15-nMEmi2 T545/
551A was sufficient to cause M phase arrest in cycling extracts
even without Mos addition, whereas wild-type (WT) Emi2 was
unable to do so at this dose (Fig. 2D) (a nondestructible Emi2
fragment was used in this experiment to circumvent the Mos
requirement for Emi2 stability during prolonged mitotic arrest,
as described further in Fig. 3). As observed for the Mos-induced
mitotic arrest, the Emi2 T545/551A-induced arrest was typified
by stabilization of cyclin B, but not cyclin A (Fig. 2D).
In principle, Mos could oppose T545/551 phosphorylation
either by retarding Cdc2-mediated phosphorylation of these
residues or enhancing their dephosphorylation. We did not
observe any effects of Mos on the activity of Cdc2 toward Emi2’s
C terminus (data not shown). To examine the effects of Mos on
dephosphorylation of these sites, we prephosphorylated a large
fragment of Emi2 (amino acids 326–651) by using Cdc2/cyclin B
and radiolabeled ATP. This fragment contains no other S/T-P
sites, and Cdc2 does not phosphorylate the T545/551Amutant in
vitro (data not shown). The radiolabeled GST-Emi2 was added
to the interphase egg extracts supplemented with either MBP or
MBP-Mos. Addition of Mos to extracts significantly accelerated
Emi2 dephosphorylation at T545/551 (Fig. 2E). Collectively,
these data suggest that Mos promotes CSF arrest, at least in part,
by keeping Emi2 dephosphorylated and bound to the APC.
Mos Enhances Dephosphorylation of Multiple Cdc2 Sites That Control
Emi2 Stability. Although Mos promoted Emi2 activity, we also
observed that Emi2 stability was affected by MAPK inhibition
in CSF extracts (Fig. 2B). An established series of biochemical
events (CaMKII and Plx1 phosphorylation, recognition by
TrCP) promotes rapid Emi2 degradation during Ca2-
mediated release from CSF arrest. However, the signals regu-
lating the slow degradation of Emi2 during mitotic arrest that
could potentially be targeted by Mos have not been established.
To identify regions of Emi2 regulating its stability during CSF
arrest, we produced a panel of in vitro translated (IVT), radio-
labeled Emi2 deletion mutants and assessed their stabilities in
CSF-arrested extracts. Fragments of Emi2 spanning amino acids
1–431 or 1–350 were as stable as full-length Emi2 in CSF extracts
(Fig. 3A and SI Fig. 8A). However, fragments spanning amino
acids 1–321 or 1–279 were slowly destroyed over a 1- to 2-h
period. This slow degradation required the previously mapped
N-terminal degron on Emi2; mutation of this degron (DS33AA)
restored Emi2 (amino acids 1–279) stability (SI Fig. 8B). When
we further deleted the C terminus of Emi2 (amino acids 1–203),
the protein became stable again. All fragments still contained
192RSST and 32DSGYSDS motifs for phosphorylation by
CaMKII and Plx1 and were rapidly destroyed upon calcium
addition, and all were stable in the interphase extracts (data not
shown). These data suggested that a region of Emi2 between
residues 204 and 279 might promote Emi2 degradation during
prolonged mitoses and raised the possibility that a region
between amino acids 322 and 350 could stabilize Emi2 by
antagonizing the activity of the 204–279 region.
To determine how the region between amino acids 322 and
350 might affect Emi2 stability, we mutated several conserved
residues (Fig. 3A). Mutating RR332/333 or ST335/336 to Ala
destabilized Emi2 in CSF extracts (Fig. 3B). These data are
interesting in light of recent reports suggesting that Rsk can
phosphorylate S335/T336 of Emi2 (18) to promote Emi2 stabil-
ity. The consensus site for phosphorylation by Rsk is R-X-X-S/T,
so the RR333AA mutation also might have disrupted Emi2
phosphorylation by Rsk.
Although Cdc2 can modulate Emi2–APC interaction, we also
reported that high Cdc2 kinase activity could promote Emi2
Fig. 3. A group of Cdc2 sites controlling slow Emi2 degradation are dephosphorylated in response to Mos/MAPK signaling. (A) A series of Emi2 deletion mutants
was made to examine the stability of radiolabeled Emi2 fragments in CSF extracts. Constructs listed as stable in CSF extracts were as stable as full-length Emi2.
The 1–321 and 1–279 proteins were unstable (SI Fig. 6A). The sequence of Xenopus Emi2 (amino acids 322–350) was aligned with four other species, and the
conserved residues are highlighted. (B) Indicated radiolabeled IVT Emi2 proteins were added to CSF extracts and incubated at room temperature. Samples were
taken at indicated times and examined by SDS/PAGE and autoradiography. (C) Indicated Emi2 proteins were processed as in B. (D) Indicated Emi2 proteins were
processed as in B. (E) Radiolabeled IVT Emi2 (WT, 4AP, or ND) proteins were added into CSF extract pretreated for 30 min at room temperature with DMSO or
250 M U0126. Samples were taken at indicated times after IVT protein addition, and 35S-labeled Emi2 was detected by SDS/PAGE and autoradiography. (F)
GST-Emi2 (164–651, T545/551A) protein was processed as in Fig. 2E except that each column represents the average of four replicates.
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destabilization. Therefore, we mutated multiple candidate Cdc2/
cyclin B sites between amino acids 204 and 279 within the context
of the mitotically unstable amino acids 1–279 fragment and
observed their degradation in CSF extracts. Mutation of any of
these sites alone somewhat stabilized the Emi2 fragment (SI Fig.
8C). However, combined mutation of all four sites to Ala
(S213A, T239A, T252A, and T267A; hereafter referred to as
4AP) effectively stabilized the 1–279 fragment, consistent with
the idea that Cdc2-mediated phosphorylation of these sites
might favor Emi2 destabilization (Fig. 3C). Indeed, artificially
elevating Cdc2 kinase activity through the addition of cyclin B to
the extract promoted slow Emi2 degradation, and this process
was abrogated by the 4AP mutation (SI Fig. 8D). Importantly,
when the 4AP mutation was examined in the context of full-
length Emi2 containing mutations at 335/336, we found that the
4AP mutation compensated for mutation of 335/336, stabilizing
Emi2 even in the absence of Rsk-mediated phosphorylation (Fig.
3D). These data raised the possibility that Rsk phosphorylation
promotes Emi2 stability by protecting the 204–279 region of
Emi2 from phosphorylation by Cdc2.
To further assess the involvement of the Mos/MAPK pathway
in controlling Emi2 stability through the 213/239/252/267 sites,
we analyzed the effects of MAPK pathway inhibition on the
stability of WT and 4AP proteins. Treatment of CSF extracts
with U0126 destabilized Emi2, and this effect was abrogated in
the 4AP mutant (Fig. 3E). Again this destruction occurred
through the known phosphodegrons for TrCP recognition,
presumably after phosphorylation by Plx1, because mutation of
DS33 and DS284 to Ala [nondegradable Emi2 (ND)] prevented
U0126-induced Emi2 degradation. The Emi2 degron mutant
also allowed visualization of more highly phosphorylated forms
of Emi2 (Fig. 3E and SI Fig. 8B), which are normally seen after
extensive phosphorylation by Plx1 during calcium-dependent
Emi2 destruction (6). These highly phosphorylated forms of
Emi2 were not seen with the 4AP mutant, suggesting a sequence
of events wherein phosphorylation of Emi2 by Cdc2 primes Emi2
for interaction with Plx1, similar to the destruction mechanism
for Emi1 (19). These data suggest that the Mos/MAPK/Rsk
pathway regulates Emi2 stability through antagonizing phos-
phorylation at the 213/239/252/267 Cdc2 sites, thereby prevent-
ing further phosphorylation by Plx1.
Because Mos activity enhanced dephosphorylation of the
545/551 sites, we hypothesized that Mos also might promote
Emi2 stabilization by enhancing Emi2 dephosphorylation, but in
this case at the 213/239/252/267 sites. To examine dephosphor-
ylation of these sites in the absence of the 545/551 sites (and also
in the absence of additional uncharacterized S-P and T-P sites in
the Emi2 N terminus), we phosphorylated a GST-164–651
fragment of Emi2 (T545/551A) by using recombinant Cdc2/
cyclin B and [-32P]ATP and added this protein to interphase
extracts in the presence or absence of supplementary Mos. As
shown in Fig. 3F, Mos promoted more rapid dephosphorylation
of this Emi2 protein. Thus, Mos may control Emi2 stability
during CSF arrest through enhancing the dephosphorylation of
213/239/252/267 sites.
Mos Promotes PP2A–Emi2 Interaction. As described previously,
deletion analysis revealed that the region of Emi2 containing the
Rsk phosphorylation sites was important for regulating Emi2
stability. Indeed, adding an excess of an Emi2 fragment spanning
this region [stability domain (SD), amino acids 319–375] to CSF
extracts resulted in the failure to maintain CSF arrest as indi-
cated by cyclin B levels, Cdc2 activity, and DNA morphology
(Fig. 4A). This exit was accompanied by a greater than usual
upshift in Emi2 mobility and some Emi2 destruction before
Emi2 returned to its interphase mobility (Fig. 4A). These data
suggested that this region might compete with endogenous Emi2
for some factors important for Emi2 activity and stability.
Previously, we examined the interactions between Emi2 and PP1
and between Emi2 and PP2A and found that Emi2 could bind
to PP2A, but not to PP1 (12). Given our findings implicatingMos
in regulating Emi2 dephosphorylation, we postulated that Mos
might direct PP2A binding and that phosphorylation of this
region by Rsk might mediate this effect. We observed binding of
PP2A to the Emi2 319–375 fragment in CSF extract (SI Fig. 9A).
Similarly, IVT 1–350 Emi2, but not 1–321 Emi2, coimmunopre-
cipitated with PP2A from Mos-supplemented interphase ex-
tracts (SI Fig. 9B), correlating with our observation that a region
within residues 322–350 confers Emi2 stability in CSF extract.
Therefore, determinants of PP2A binding to Emi2 lay within the
region phosphorylated by Rsk and implicated in Mos control of
Emi2.
If Mos/MAPK signaling acted through PP2A, we expected to
see effects of Mos on PP2A binding to Emi2. Indeed, treatment
of CSF extracts with U0126 impeded the binding of recombinant
Emi2 to endogenous PP2A (Fig. 4B). Collectively, these data
strongly suggest that Mos can control Emi2 by regulating binding
to PP2A.
Rsk Phosphorylation Affects Emi2 Through Its Ability to Confer PP2A
Binding. Although our data demonstrated that Mos could en-
hance Emi2–PP2A interaction, they did not demonstrate that
this was the primary function of Rsk-mediated Emi2 phosphor-
ylation. Consistent with a role for Rsk phosphorylation in
conferring PP2A binding, the ability of Mos to enhance the
interaction of the Emi2 319–375 fragment with PP2A in inter-
phase extracts was lost after mutation of the Rsk phosphoryla-
tion sites S335 and T336 (Fig. 4C). Proximal to these Rsk
phosphorylation sites is a 342SQSEmotif conserved among Emi2
orthologues (Fig. 3A). S342 and S344 were recently suggested to
be additional sites for phosphorylation by Rsk based on the
effect of S342A and S344A mutations on Emi2 gel mobility in
CSF extract. However, we found that mutation of S342/344 to
Ala had no effect on in vitro phosphorylation of Emi2 by Rsk, but
largely abrogated binding to PP2A (Fig. 4 D and E).
This identification of a mutant that retained Rsk phosphor-
ylation, but lacked PP2A binding, afforded us the opportunity to
determine whether Mos effects on Emi2 were exerted primarily
at the level of PP2A binding. As shown in Fig. 4F, Emi2
ST336AA and Emi2 S342/344A were equally unstable in CSF
extract, whereas Emi2 WT protein was stable. We also found
that Emi2 ST336AA and Emi2 S342/344A were both markedly
impaired in their ability to bind the APC (Fig. 4G). Thus, our
data demonstrate that the major function of Mos in CSF arrest
is, through Rsk, to promote Emi2–PP2A interaction and thus
antagonize phosphorylation of Emi2 by Cdc2/cyclin B. In this
manner, Emi2 is kept sufficiently stable and has sufficient
APC-inhibitory activity to promote and maintain CSF arrest
(Fig. 4H).
Discussion
The arrest of vertebrate eggs in meiotic metaphase II depends on
CSF activity, of which the protein kinase Mos is a key compo-
nent. It is now clear that Mos exerts its effects, in large part, by
promoting Rsk-mediated phosphorylation of Emi2. We have
shown here that an important function of theMos/MEK/MAPK/
Rsk signaling cascade is to promote the PP2A-mediated dephos-
phorylation of Cdc2 phosphorylation sites on Emi2 that modu-
late Emi2 activity and stability.
Maintenance of CSF Arrest Requires Active Mos Signaling.The ability
of Mos to regulate dephosphorylation of sites important for
maintaining CSF arrest supports a role for Mos in CSF main-
tenance. This finding agrees with studies in metaphase II-
arrested mouse eggs, in which sustained U0126 treatment caused
parthenogenetic activation (20). Previous reports suggesting that
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MAPK signaling is unnecessary for CSF maintenance in Xeno-
pus extracts used 50 MU0126 for 30–60 min (21, 22). However,
when we used U0126 at higher concentrations (200–300 M) for
longer periods of time (2–3 h), we found that more complete
MAPK inhibition in CSF extract in fact caused eventual cyclin
B degradation, agreeing with a recent report that immunological
neutralization of Mos function also caused spontaneous mitotic
exit (23).
It has been reported that CSF extracts immunodepleted of
Rsk2 maintain CSF arrest (4). Similar to previous reports using
U0126, the depleted extract was only incubated for 60 min, which
may not be enough time to allow Emi2–PP2A complex dissoci-
ation and Cdc2-dependent Emi2 inactivation. Alternatively,
other Rsk isoforms or even unrelated kinases may compensate
for the loss of Rsk2 and help maintain Emi2–PP2A interaction.
The conservation among vertebrate Emi2 orthologues at the
sites for Rsk phosphorylation and PP2A binding (Fig. 3A)
suggests that CSF arrest by Emi2 is maintained through a similar
mechanism in mammalian systems.
Mos Enhances Emi2 Dephosphorylation.We found that Cdc2/cyclin
B can regulate Emi2 through both C-terminal phosphorylation
(T545/551) and a cluster of N-terminal phosphorylation sites.
For both the N- and C-terminal sites, Mos accelerated their
dephosphorylation. The ability of Mos to enhance PP2A-
mediated Emi2 dephosphorylation appears to lie, at least in part,
at the level of PP2A–Emi2 binding, in that Mos activity pro-
moted PP2A–Emi2 interaction and mutation of the Rsk phos-
phorylation sites abrogated this effect. It is also possible thatMos
signaling might somehow enhance PP2A’s enzymatic activity or
dampen the activity of Cdc2/cyclin B during CSF arrest perhaps
through activation of Wee1 by MAPK (24).
We also observed background phosphatase activity toward
Emi2 in interphase extracts (Figs. 2E and 3F), which could result
from residual Mos in the extract. Alternatively, PP2A or another
phosphatasemay exert some degree ofMos-independent activity
toward Emi2. If so, the Mos-dependent recruitment of PP2A to
Emi2 during CSF arrest would tip the balance of Emi2-directed
kinase and phosphatase activities in favor of dephosphorylation,
thereby preserving Emi2 function in the face of constant Cdc2/
cyclin B activity. Mos-mediated enhancement of the Emi2–PP2A
interaction does not result in complete Emi2 dephosphorylation
because Emi2 in CSF or Mos-supplemented cycling extracts still
displays a slight retardation in gel mobility. This phosphorylation
and its relevance for Emi2 function have not been characterized.
Control of Emi2 Protein Stability. At the time of fertilization-
induced exit from CSF arrest, Emi2 is rapidly degraded. Despite
this susceptibility to precipitous degradation, Emi2 is not par-
ticularly unstable at other phases of the cell cycle. Phosphory-
lation of Emi2 at residues S213, T239, T252, and T267 by Cdc2
increases its basal mitotic instability. Thus, the feedback loop,
whereby Cdc2 enhances APC activity to permit slow cyclin
degradation during CSF arrest, might work by both antagonizing
Emi2-APC association and facilitating limited Emi2 turnover.
Importantly, Mos enhanced dephosphorylation of Emi2 at
these Cdc2 sites presumably by promoting Emi2–PP2A interac-
tion. Mutation of these Cdc2 sites restored the stability in CSF
Fig. 4. The Mos/MAPK/Rsk pathway promotes interaction of Emi2 with PP2A. (A) CSF extracts were preincubated for 5 min with 0.5 mg/ml GST or GST-Emi2
(amino acids 319–375, SD), after which IVT 35S-labeled Emi2 was added to the extract. Samples were taken at indicated times to detect cyclin B2 and added GST
by immunoblotting, Cdc2 kinase activity, and full-length Emi2 tracer by autoradiography. In addition, samples were taken to examine Hoechst-stained nuclei
supplemented into the extract. (Scale bars: 25 m.) (B) MBP or MBP-Emi2N (amino acids 1–350) prebound to amylose resin was added to CSF extracts in the
presence of DMSO or 250 M U0126. After 30 min of incubation at room temperature, the beads were washed, and bound PP2A was examined by
immunoblotting. (C) Indicated GST-SD proteins prebound to glutathione Sepharose were incubated in interphase extracts pretreated with MBP or Mos protein.
After incubation, beads were retrieved and washed, and bound PP2A was examined by immunoblotting. (D) Indicated GST-SD prebound to glutathione
Sepharose was phosphorylated in vitro by using recombinant Rsk and [-32P]ATP. After washing, proteins were separated by SDS/PAGE. Proteins were Coomassie
blue stained, and incorporated 32P was detected by autoradiography. (E) Indicated GST-SD proteins were incubated in CSF extracts and handled as in B. (F)
Indicated radiolabeled IVT Emi2 was added to CSF extracts and incubated at room temperature. Samples were taken at indicated times, and levels of 35S-labeled
Emi2 were examined by SDS/PAGE and autoradiography. (G) Indicated radiolabeled IVT Emi2 were mixed into CSF extracts. After 2 h of incubation at 4°C, Cdc27
was immunoprecipitated and washed, and bound IVT Emi2 was examined by SDS/PAGE and autoradiography. (H) Mos-activated Rsk phosphorylates Emi2 at S335
and T336. This phosphorylation promotes Emi2–PP2A association, enhancing Emi2 dephosphorylation at both N- and C-terminal Cdc2 phosphorylation sites.
Dephosphorylation of the N-terminal sites promotes Emi2 stability. Dephosphorylation of the C-terminal sites enhances APC-inhibitory binding of Emi2.
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extract of an Emi2 mutant lacking Rsk phosphorylation sites and
thus deficient in PP2A interaction. These data support a model
wherein PP2A keeps Emi2 in a stable configuration during CSF
arrest, which seems at odds with our previous report that
phosphatase inhibition using okadaic acid (OA) promoted Emi2
inactivation, but not destruction, in CSF extracts (13). However,
Emi2 inactivation in those experiments was rapid because cyclin
B destruction was complete only 10 min after OA treatment,
whereas Cdc2/cyclin B-driven Emi2 destruction takes 1–2 h to
occur (Fig. 3 B–E). We have found that Emi2 is indeed desta-
bilized in OA-treated CSF extracts, provided that cyclin destruc-
tion is prevented by APC ectopic inhibition (data not shown).
Addition of excess cyclin B to CSF extracts overrides PP2A’s
control of both Emi2 activity and stability. The N-terminal Cdc2
sites that regulate Emi2 stability may be less readily phosphor-
ylated (or more readily dephosphorylated) than the C-terminal
Cdc2 sites that regulate Emi2 activity. Indeed, excess cyclin B
promotes Emi2 inactivation in CSF extracts when added at
concentrations (25–50 nM) lower than those required for Emi2
destabilization (75 nM). This may explain why Emi2 is only
partially degraded upon MAPK inhibition or competition of
PP2A away from endogenous Emi2 (Figs. 2B, 3E, and 4A).
APC-inhibitory activity is the property of Emi2 more sensitive
to Cdc2/cyclin B, and the resulting degradation of cyclin B
prevents Emi2 from being completely destroyed.
When interphase extracts are pretreated with OA and then
induced to enter mitosis by using nondegradable cyclin B, an
uncharacterized inhibitor of mitotic proteolysis (IMP) blocks
APC activity (25). Because Emi2-mediated CSF arrest is OA-
sensitive, rather than OA-dependent, it seems unlikely that Emi2
and IMP are identical.
Mos/Emi2 and the Regulation of M Phase in Embryonic Cells. In
cycling extracts, Emi2 is not precipitously degraded at M phase
exit (8). The 10- to 15-min duration of M phase is too brief to
permit significant Emi2 degradation through the Cdc2/cyclin
B-dependent mechanism described here. It does appear that
Cdc2-dependent Emi2–APC dissociation is critical to enable
embryonic M phase exit because the level of endogenous Emi2
is sufficient to induce metaphase arrest in the presence of ectopic
Mos, and endogenous levels of ectopic Emi2 T545/551A mutant
induce M phase arrest even in the absence of Mos. The fact that
MAPK levels are elevated in early embryonic mitoses raises the
question of why MAPK does not promote arrest through Emi2
in these early M phases. However, because Cdc2 activation
temporally precedes MAPK activation (SI Fig. 7A) and there is
a lag between activating these kinases (4, 26), the most straight-
forward possibility is that Cdc2 promotes dissociation of Emi2
from the APC and the APC becomes active before Rsk would
phosphorylate Emi2. Thus, MAPK pathway activity may be of
significance for Emi2 regulation only in meiotic transitions.
Materials and Methods
Cloning and Protein Expression. Cloning, expression, and purifica-
tion of Mos or Emi2 fragments into pMAL-c2X and Emi2
fragments into pGEX-KG were as described (12, 13, 21). GST-
Emi2 cloned into pCS2 was transcribed and translated in vitro
by using Promega’s (Madison, WI) TNT SP6 high-yield protein
expression system.
35S-labeled Emi2 proteins were generated by using the TNT
quick-coupled transcription/translation system (Promega) in the
presence of radiolabeledMet/Cys (MPBiomedicals, Irvine, CA).
Emi2 mutagenesis was performed by using the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA).
Protein Analyses. Antibodies used were rabbit anti-Emi2 (27),
mouse anti-cyclin B2 (28), mouse anti-cyclin A (no. 11041;
Abcam, Cambridge, MA), mouse anti-PP2A (no. 05–421; Up-
state Biotechnology, Lake Placid, NY), rabbit anti-phospho-
MAPK (no. 9106; Cell Signaling Technology, Danvers, MA),
rabbit anti-phospho-Cdc2 (no. 9111; Cell Signaling Technology),
and mouse anti-Cdc27 (no. 9972; Santa Cruz Biotechnology,
Santa Cruz, CA).
To examine Rsk-mediated Emi2 phosphorylation, recombi-
nant Rsk2 (Upstate Biotechnology) and glutathione Sepharose-
bound GST-Emi2 proteins were incubated in kinase buffer [10
mM TrisHCl (pH 7.5), 10 mMMgCl2, 1 mM DTT, and 100 M
ATP] in the presence of 5 Ci [-32P]ATP at room temperature
for 30 min. The beads were washed in PBS plus 300 mM NaCl
and 0.1% Triton and eluted with SDS/PAGE sample buffer.
[32P]Emi2 was detected by phosphorimager.
For dephosphorylation, GST-Emi2 proteins were prebound to
glutathione Sepharose beads and incubated with recombinant
Cdc2/cyclin B (New England Biolabs, Ipswich, MA) in kinase
buffer in the presence of 25 Ci [-32P]ATP at room tempera-
ture for 30 min. The beads were washed [10 mMHepes (pH 7.7),
250 mM sucrose, 2.5 mM MgCl2, 1 mM DTT, and 50 mM KCl]
and incubated in interphase extracts pretreated with either MBP
orMos. Aliquots were retrieved, and the beads were washed with
PBS plus 300 mM NaCl and 0.1% Triton, eluted with SDS/
PAGE sample buffer, resolved by SDS/PAGE, and detected by
phosphorimager.
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